• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Jim O. Prochaska, director, Cancer Prevention Research Center, and founder, Pro-Change Behavior Systems

Article

As wellness and prevention color the DM landscape, Jim Prochaska is in line as creator of the Transtheoretical Model of Behavior Change.

Jim O. Prochaska, PhD
Director, Cancer Prevention Research Center
Founder, Pro-Change Behavior Systems
Kingston, R.I.

As the author of more than 300 publications and a professor of clinical and health psychology at the University of Rhode island, Prochaska works tirelessly to merge the theory, science and practice of behavior. He anticipates that DM of the future will move from behavior change-lite to more adoption of the behavior change model by organizations over the continuum of care.

He earned B.A., M.A., and his Ph.D. degrees from Wayne State University in Detroit in clinical psychology.

Related Content
© 2024 MJH Life Sciences

All rights reserved.